Anthony Claude Antonelli

Anthony Claude Antonelli

Auto-generated profile, based on publicly available information

Anthony Claude Antonelli

Immunology Program; Sloan Kettering Institute; New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AAAnthony C. Antonelli
Anthony C. Antonelli
ABAnna Binyamin
Anna Binyamin
THTobias M. Hohl
Tobias M. Hohl
MGMichael S. Glickman
Michael S. Glickman
GRGil Redelman-Sidi
Gil Redelman-Sidi
Significance: Bacillus Calmette–Guérin (BCG) therapy is one of the oldest tumor immunotherapies, but its mechanism remains unknown. Herein we show that BCG therapy induces tumor-specific T cell-dependent immunity that is predominantly mediated by CD4 T cells in a manner distinct from other tumor immunotherapies. These immunologic insights may allow investigation into biomarkers that could predict the efficacy of BCG in human cancer patients.

30 August 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
For decades, BCG immunotherapy has been the standard of care for non–muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role for CIITA in controlling MHC-II antigen presentation machinery, the requirement for CIITA is independent of MHC-II and associated genes. Rather, we find that CIITA is required for a broader tumor-intrinsic transcriptional program linked to critical pathways of tumor immunity via mechanisms that remain to be determined. Tumor cell intrinsic expression of CIITA is not required for a response to immunotherapy targeting programmed cell death protein 1 (PD-1), suggesting that different modalities of immunotherapy for bladder cancer could be employed based on tumor-intrinsic characteristics.

21 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAndrew W. Daman
Andrew W. Daman
AAAnthony Claude Antonelli
Anthony Claude Antonelli
GRGil Redelman-Sidi
Gil Redelman-Sidi
LPLucinda Paddock
Lucinda Paddock
JCJin Gyu Cheong
Jin Gyu Cheong
MGMichael S. Glickman
Michael S. Glickman
Summary: Mycobacterium bovis BCG is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC-reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder in both mice and humans reprograms HSPCs to amplify myelopoiesis and functionally enhance myeloid cell antigen presentation pathways. Reconstitution of naive mice with HSPCs from bladder BCG-treated mice enhances anti-tumor immunity and tumor control, increases intratumor dendritic cell infiltration, reprograms pro-tumorigenic neutrophils, and synergizes with checkpoint blockade. We conclude that bladder BCG acts systemically, reprogramming HSPC-encoded innate immunity, highlighting the broad potential of modulating HSPC phenotypes to improve tumor immunity. Graphical

29 September 2025 in bioRxiv
Verified
Preprint
Open access
BXBaixue Xiao
Baixue Xiao
SKSoojin Kim
Soojin Kim
BLBenjamin I Laufer
Benjamin I Laufer
AAAnthony Antonelli
Anthony Antonelli
MHMilena Hornburg
Milena Hornburg
MEMaheswara Reddy Emani
Maheswara Reddy Emani
Lipid nanoparticles (LNPs) are a powerful drug delivery platform advancing vaccines and gene therapies. While their efficacy and safety has been found to be closely linked to innate immune activation, current in vitro models are unable to predict immune responses reliably. Conventional models, such as PBMCs, are limited by donor variability and inconsistent sensitivity. To address this, we developed a cytokine profiling platform using induced pluripotent stem cell (iPSC)-derived monocytes (iMonocytes), a physiologically relevant innate immune cell type that plays a key role in immune surveillance and inflammation. iPSCs provide a renewable, uniform monocyte source for consistent, high-sensitivity LNP screening. When tested with LNPs of graded immunostimulatory potency, iMonocytes showed improved reproducibility and strong correlation with in vivo cytokine responses. This platform enables evaluation of cargo- and dose-dependent effects, providing a robust and scalable tool for preclinical assessment and rational design of LNP therapeutics.

4 April 2023
Verified
Other
Open access
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
For decades, BCG immunotherapy has been the standard of care for non–muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role for CIITA in controlling MHC-II antigen presentation machinery, the requirement for CIITA is independent of MHC-II and associated genes. Rather, we find that CIITA is required for a broader tumor-intrinsic transcriptional program linked to critical pathways of tumor immunity via mechanisms that remain to be determined. Tumor cell intrinsic expression of CIITA is not required for a response to immunotherapy targeting programmed cell death protein 1 (PD-1), suggesting that different modalities of immunotherapy for bladder cancer could be employed based on tumor-intrinsic characteristics.

4 April 2023
Verified
Other
Open access
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II